Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better…

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|24|3901-3913

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.24, 2014-05, pp. : 3901-3913

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-epidermal growth factor receptor drugs in cancer therapy

By Tortora Giampaolo   Ciardiello Fortunato  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 6, 2002-06 ,pp. : 755-768

Informa Healthcare

Access to resources Recommend Favorite

Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients

By  

Current Drug Targets, Vol. 15, Iss. 13, 2014-12 ,pp. : 1225-1230

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 731-745

Bentham Science Publishers

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy

By  

Current Drug Targets, Vol. 11, Iss. 8, 2010-01 ,pp. : 1000-1017

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-angiogenic activity of salvicine

By Zhang Yanli   Wang Lei   Chen Yajuan   Qing Chen  

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 51, Iss. 8, 2013-08 ,pp. : 1061-1065

Informa Healthcare

Access to resources Recommend Favorite